Рет қаралды 261
Public health’s commitment to evidence-based policies and interventions has gained renewed significance in the “post-truth” era of MAGA-style politics in the United States. However, many scholars and service providers remain ignorant to some of the key limitations of the evidence they rely on to conduct their work. In the field of harm reduction, the most significant restriction narrowing the scope of research and intervention is the field’s reluctance to engage with people who sell drugs. Focusing almost exclusively on people who use drugs, public health and harm reduction have relinquished key questions of political and public health import concerning drug selling, mixing, adulteration, and transportation to criminal justice agencies, especially the Drug Enforcement Administration (DEA) and local police forces. In other words, public health has been relegated to the downstream management of substance use, while law enforcement agencies monopolize the upstream assessment of narcotics supply chains. What does it entail to incorporate people who sell drugs into harm reduction research and intervention? What can be done both informally at the local level, and formally at the legislative level, to develop a program of “supply-side harm reduction” in the United States?
Speaker:
Fernando Montero, Chief T32 Postdoctoral Research Fellow at the HIV Center for Clinical and Behavioral Studies at Columbia University
Recording date: February 22, 2024
For more educational content, check out our main channel at / drugpolicyalliance
The Drug Policy Alliance is building a world without the drug war where people who use drugs are supported, not punished. We’re building a world where drug policy is grounded in evidence, health, equity, and human rights. Join us: drugpolicy.org/ .
Watch our full video catalog at bit.ly/3vGJF7E
Facebook: bit.ly/2OJS6OJ
Instagram: bit.ly/3rZmXoT
LinkedIn: bit.ly/3yhrKH6
TikTok: bit.ly/3JeLEZx
Twitter: bit.ly/2Qdm3XH